TXG — 10X Genomics Share Price
Last Trade - 00:00- $17.84bn
- $17.21bn
- $298.85m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 71.08 | 146.31 | 245.89 | 298.85 | 497.87 | 685.53 | 61.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
10x Genomics, Inc. is a life science technology company. The Company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The Company’s product consists of chromium single cell gene expression solution, cell immune profiling solution, cell copy number variation (CNV) solution, Cell assay for transposase accessible chromatin (ATAC) solution. The Company’s Chromium platform enables analysis of individual biological components, such as up to millions of single cells. Its Visium platform is designed to identify where biological components are located and how they are arranged with respect to each other. Its molecular assays are used with its Chromium platform, and with its planned Visium platform, to provide sensitive and robust biochemistries that convert minute amounts of biological analytes into detectable signals.
Directors
- John Stuelpnagel (63)
- Benjamin Hindson PRE (46)
- Serge Saxonov CEO (44)
- Justin McAnear (45)
- Jean Philibert (61)
- Eric Whitaker (54)
- Bradford Crutchfield (58)
- Ruth De Backer (44)
- Sridhar Kosaraju (43)
- Mathai Mammen (53)
- Kimberly Popovits (62)
- Bryan Roberts (54)
- Shehnaaz Suliman (49)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- January 1st, 1970
- Public Since
- January 1st, 1970
- No. of Shareholders
- 60
- No. of Employees
- 1,053
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 110,885,642
- Address
- 6230 Stoneridge Mall Road, PLEASANTON, 94588
- Web
- https://www.10xgenomics.com/
- Phone
- +1 9254017300
- Auditors
- Ernst & Young LLP
Latest News for TXG
Upcoming events for TXG
Q3 2021 10X Genomics Inc Earnings Release
Similar to TXG
LUCIRA HEALTH ORD
NASDAQ Global Select Market
MYRIAD GENETICS ORD
NASDAQ Global Select Market
NATERA ORD
NASDAQ Global Select Market
ORTHO CLINICAL DIAGNOSTICS ORD
NASDAQ Global Select Market
TRINITY BIOTECH ADR REP 4 CL A ORD
NASDAQ Global Select Market
FAQ
As of Today at 11:28 UTC, shares in 10X Genomics are trading at $162.75. This share price information is delayed by 15 minutes.
Shares in 10X Genomics last closed at $162.75 and the price had moved by +54.1% over the past 365 days. In terms of relative price strength the 10X Genomics share price has outperformed the S&P500 Index by +16.92% over the past year.
The overall consensus recommendation for 10X Genomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
10X Genomics does not currently pay a dividend.
10X Genomics does not currently pay a dividend.
10X Genomics does not currently pay a dividend.
To buy shares in 10X Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $162.75, shares in 10X Genomics had a market capitalisation of $17.84bn.
Here are the trading details for 10X Genomics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TXG
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
10X Genomics does not currently have a style classification.
The analyst consensus target price for shares in 10X Genomics is $204.63. That is 25.73% above the last closing price of $162.75.
Analysts covering 10X Genomics currently have a consensus Earnings Per Share (EPS) forecast of -$0.55 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 10X Genomics. Over the past six months, its share price has underperformed the S&P500 Index by -23.64%.
As of the last closing price of $162.75, shares in 10X Genomics were trading -4.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 10X Genomics.
10X Genomics' management team is headed by:
- John Stuelpnagel -
- Benjamin Hindson - PRE
- Serge Saxonov - CEO
- Justin McAnear -
- Jean Philibert -
- Eric Whitaker -
- Bradford Crutchfield -
- Ruth De Backer -
- Sridhar Kosaraju -
- Mathai Mammen -
- Kimberly Popovits -
- Bryan Roberts -
- Shehnaaz Suliman -
We do not have data on 10X Genomics' shareholders